Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ESTRADIOL

All products: general benefit

Other products in the same Health Canada class (G03CA) — coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, Limited Use 398
  • B + estradiol (Vagifem 10): general benefit
  • Estradiol hemihydrate (Imvexxy): general benefit

Lupin-Estradiol · DIN 02449048 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Estradiol · DIN 02449048 Manufacturer: Lupin Pharma Canada Limited; listing date 2016-04-29 Health Canada: Marketed since 2016-02-29 · brand LUPIN-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 0.5 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Lupin-Estradiol: Formulary list price $0.1199/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1199 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93486 · Verify on the e-Formulary ↗ (DIN 02449048)

Source record
DIN 02449048: Lupin-Estradiol Raw flags: sec3=Y Item: 681600051; group id 733; item number 1797; lccId None; manufacturer id LUP Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.1199; ministry $0.1199 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449048 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93486
Interchangeable products
Estrace · DIN 02225190 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:16 Estrogens) and how they are covered

Matched class: 68:16 Estrogens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE & PROGESTERONE Some products covered without a code (check the product listing): CONJUGATED ESTROGENS 68:16 Estrogens

CONJUGATED ESTROGENS

· 2 products · Limited Use, codes 398 (1), General benefit (1) · strengths: 0.625mg, 0.625mg/g · SR Tab, Vag Cr

ESTRADIOL 17-B

· 1 products · General benefit · strengths: 10mcg · Vag Tab with Applicator

ESTRADIOL HEMIHYDRATE

· 2 products · General benefit · strengths: 4mcg, 10mcg · Vag Insert

ESTRADIOL HEMIHYDRATE & PROGESTERONE

· 1 products · General benefit · strengths: 1mg & 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:16
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications ESTRING (17 β-estradiol) is indicated for postmenopausal urogenital complaints due to estrogen deficiency such as feeling of dryness in the vagina (atrophic vaginitis) with or without pruritus vulvae, dyspareunia, dysuria and urinary urgency (atrophic mucosa in the urethra and trigonum). ESTRING should be prescribed with an appropriate dosage of a progestin for women with intact uteri, in order to prevent endometrial hyperplasia/carcinoma. The maximum recommended duration of continuous therapy is 2 years. 1.1. Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years of age): There have not been sufficient numbers of geriatric patients involved in studies utilizing ESTRING to determine whether those over 65 years of age differ from younger subjects in their response to ESTRING (See 7 Warnings and Precautions: Special Populations: Geriatrics). https://pdf.hres.ca/dpd_pm/00083118.PDF PM date: 2026-01-08 Source product: ESTRING; DIN 02168898; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.